Company intelligence / Profile preview

Universal Cancer Technologies

Ontario, Canada

Ownership: Private
Development stage: Other

Overview

UCT has developed a highly sensitive blood-based diagnostic test for the CA-62 biomarker, capable of detecting most types of epithelial cancer at all stages, with specificity and sensitivity confirmed on ~10,000 human samples.

Therapeutic areas: Oncology
Modalities: Diagnostic test (In-vitro diagnostics, Cancer biomarker assay)
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Universal Cancer Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Universal Cancer Technologies.

Explore the full profile